Updating results

117 results for metastatic breast cancer Sort: Relevance | Date

Early and locally advanced breast cancer: diagnosis and management (NG101)

Evidence-based recommendations on diagnosing and managing early and locally advanced breast cancer

NICE guideline Published July 2018

Advanced breast cancer

Everything NICE has said on diagnosing and treating advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated March 2018

Early and locally advanced breast cancer

Everything NICE has said on diagnosing and treating early and locally advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated July 2018

Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)

Evidence-based recommendations on the use of trastuzumab (Herceptin) for the treatment of advanced breast cancer

Technology appraisal guidance Published March 2002

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

Technology appraisal guidance Published December 2016

Gemcitabine for the treatment of metastatic breast cancer (TA116)

Evidence-based recommendations on gemcitabine (Gemzar) for treating metastatic breast cancer

Technology appraisal guidance Published January 2007

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course

Technology appraisal guidance Published March 2018

Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic breast cancer

Technology appraisal guidance Published December 2011

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published August 2012

Advanced breast cancer: diagnosis and treatment (CG81)

Evidence-based recommendations on diagnosing and treating advanced (stage 4) breast cancer (invasive adenocarcinoma) for women and men

Clinical guideline Published February 2009 Last updated August 2017

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published February 2011

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

Evidence-based recommendations on fulvestrant (Faslodex) for untreated locally advanced or metastatic (secondary) oestrogen-receptor positive breast cancer in

Technology appraisal guidance Published January 2018

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive, locally recurrent or metastatic (secondary) breast cancer in adults

Technology appraisal guidance Published March 2018

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for treating advanced HER2-positive breast cancer that has been treated before

Technology appraisal guidance Published July 2017 Last updated November 2017

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

Technology appraisal guidance Published December 2017

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor

Technology appraisal guidance Published December 2017

Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)

In development [GID-TA10366] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (locally advanced, metastatic) - eribulin (after chemotherapy) [ID964]

In development [GID-TA10030] Expected publication date: 21 December 2016

Technology appraisal guidance In development

ESNM13: Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab

Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

Evidence summary Published March 2013

Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

Evidence-based recommendations on diagnosing and managing metastatic malignant disease (cancer) of unknown primary origin in adults

Clinical guideline Published July 2010

Metastatic malignant disease of unknown primary origin

Everything NICE has said on diagnosing and managing metastatic malignant disease of unknown primary origin in an interactive flowchart

NICE Pathway Published January 2013 Last updated July 2018

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

Evidence-based recommendations on familial (inherited) breast cancer and related risks for people with a family history of breast cancer

Clinical guideline Published June 2013 Last updated March 2017

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive breast cancer in adults

Technology appraisal guidance Published December 2016

Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours

Technology appraisal guidance Published October 2012

Neutropenic sepsis: prevention and management in people with cancer (CG151)

Evidence-based recommendations on preventing and managing neutropenic sepsis in people with cancer who are having anticancer treatment

Clinical guideline Published September 2012

Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

Evidence-based recommendations on trastuzumab (Herceptin) for treating adenocarcinoma (HER2-positive metastatic gastric cancer/stomach cancer)

Technology appraisal guidance Published November 2010

Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery for adults with early breast cancer

Technology appraisal guidance Published January 2018

Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

Evidence-based recommendations on brachytherapy as the only type of adjuvant radiotherapy for breast cancer after local excision

Interventional procedures guidance Published July 2008

Laparoscopic mobilisation of the greater omentum for breast reconstruction (IPG253)

Evidence-based recommendations on laparoscopic mobilisation of the greater omentum (keyhole surgery) for breast reconstruction

Interventional procedures guidance Published February 2008

Menopause: diagnosis and management (NG23)

Evidence-based recommendations on the diagnosis and management of the menopause.

NICE guideline Published November 2015

Metastatic spinal cord compression in adults: risk assessment, diagnosis and management (CG75)

Evidence-based recommendations on the risk assessment, diagnosis and management of metastatic spinal cord compression (MSCC) in adults with cancer

Clinical guideline Published November 2008

Colorectal cancer: diagnosis and management (CG131)

Evidence-based recommendations on diagnosing and managing colorectal cancer (cancer of the colon and the rectum) in adults

Clinical guideline Published November 2011 Last updated December 2014

Microwave ablation for treating primary lung cancer and metastases in the lung (IPG469)

Evidence-based recommendations on microwave ablation for treating primary lung cancer and metastases in the lung

Interventional procedures guidance Published November 2013

Interstitial laser therapy for breast cancer (IPG89)

Evidence-based recommendations on interstitial laser therapy for treating breast cancer

Interventional procedures guidance Published September 2004

Metastatic spinal cord compression

Everything NICE has said on detecting and managing metastatic spinal cord compression in adults with cancer in an interactive flowchart

NICE Pathway Published January 2012 Last updated October 2017

Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)

Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer (keyhole removal of breast tissue)

Interventional procedures guidance Published April 2009

Image-guided radiofrequency excision biopsy of breast lesions (IPG308)

Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions to test for breast cancer

Interventional procedures guidance Published July 2009

Endoscopic axillary lymph node retrieval for breast cancer (IPG147)

Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer

Interventional procedures guidance Published December 2005

Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma (kidney cancer) after previous treatment

Technology appraisal guidance Published February 2017

Past appeals and decisions

cancer - taxanes 3 May 2000 TA054 Breast cancer - vinorelbine 15 August 2002 TBC Breast...

Published May 2018

MIB27: The Prosigna gene expression profiling assay for assessing long‑term risk of breast cancer recurrence

Advice on the use of the Prosigna gene expression profiling assay for assessing long-term risk of breast cancer recurrence to aid local decision-making

Medtech innovation briefing Published March 2015

Block scoping reports

NICE block scoping reports

Published June 2018

ES15: Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates

Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer

Evidence summary Published July 2017

Summary of decisions

We know that people are interested in the number of drugs and treatments we recommend so we publish details of our technology appraisal decisions regularly.

News Published August 2018